
Registering Clinical Trials
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: Drs Dickersin and Rennie1 called for comprehensive registration of all randomized clinical trials. They argued that such a repository would allow reciprocal transfer of knowledge between the institutions conducting the trials and the community that actively participates in the trials or has an interest in the study outcomes. It would be a matter of open record as to which studies were not yet published. Trials that are completed, but yet unpublished, could still be included in literature reviews. This would ensure a more rigorous appraisal of all the information available on a treatment.
Novartis recognises the need to share clinical trial results in an appropriate and timely manner. We have developed a policy on the communication and publication of clinical trial results that is in line with various guidelines including the Pharmaceutical Research and Manufacturers of America (PhRMA) principles on the conduct and communication of clinical trial . . . [Full Text of this Article]
Giovanni Della Cioppa, MD
Clinical Research and Development Novartis Horsham Research Centre Horsham, West Sussex, England
Jean-Jacques Garaud, MD
Clinical Research and Development Novartis Pharmaceuticals Corporation East Hanover, NJ On behalf of the Pharmaceuticals Division of the Novartis Group
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Registering Clinical Trials
Ira Leviton
JAMA. 2003;290(19):2545.
EXTRACT
| FULL TEXT
Registering Clinical TrialsReply
Kay Dickersin and Drummond Rennie
JAMA. 2003;290(19):2546.
EXTRACT
| FULL TEXT
Registering Clinical Trials
Kay Dickersin and Drummond Rennie
JAMA. 2003;290(4):516-523.
ABSTRACT
| FULL TEXT
|